Literature DB >> 18535601

An audit of conjunctival melanoma treatment in Liverpool.

B Damato1, S E Coupland.   

Abstract

PURPOSE: To evaluate treatment of conjunctival melanomas at the Ocular Oncology Service in Liverpool.
METHODS: We included 40 patients initially treated at our centre for invasive conjunctival melanoma and 36 patients referred for salvage therapy after surgery elsewhere. Patients underwent local excision or radiotherapy. Adjunctive cryotherapy for invasive and intra-epithelial neoplasia was abandoned in favour of ruthenium brachytherapy and mitomycin C chemotherapy, respectively. Tumours were staged according to circumferential spread, basal diameter, and histological thickness.
RESULTS: The 40 previously-untreated tumours were confined to bulbar conjunctiva in 31 patients and involved extrabulbar conjunctiva in 9, affecting caruncle in 6 of these. All eyes were conserved, most retaining initial visual acuity. Invasive conjunctival recurrence, which occurred in six patients, was more likely with medial tumours (Log-rank, P=0.004) and if treatment did not include radiotherapy (Log-rank, P=0.03). Four patients died of metastases, all with caruncular involvement. Of the 36 patients referred for salvage therapy after previous surgery, 11 had no visible tumour, 9 had only intra-epithelial neoplasia, and 16 had invasive melanoma, which was recurrent in seven. After salvage therapy, five patients died, all of whom were referred with recurrent invasive tumour and only one of whom had caruncular involvement.
CONCLUSIONS: Excision of invasive melanoma with adjunctive brachytherapy and topical chemotherapy achieved high rates of local tumour control with little ocular morbidity. Without caruncular involvement, disease-specific mortality was rare unless the patient was referred after a surgical procedure. Our results suggest that inadequate surgical intervention increases risks of local recurrence and metastatic death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18535601     DOI: 10.1038/eye.2008.154

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  21 in total

1.  [Conjunctival malignancies].

Authors:  Claudia Auw-Hädrich; Thomas Reinhard
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

Review 2.  [Operative therapy and irradiation of conjunctival melanoma].

Authors:  H Westekemper; D Meller; R Darawsha; S L Scholz; D Flühs; K-P Steuhl; J Hérault; J Thariat; W Sauerwein
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

3.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

Review 4.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

Review 5.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

Review 6.  Conjunctival melanoma and melanocytic intra-epithelial neoplasia.

Authors:  N Kenawy; S L Lake; S E Coupland; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

7.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04

Review 8.  Radiotherapy for ocular tumours.

Authors:  C Stannard; W Sauerwein; G Maree; K Lecuona
Journal:  Eye (Lond)       Date:  2012-11-23       Impact factor: 3.775

Review 9.  [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].

Authors:  L M Heindl; K R Koch; M Schlaak; C Mauch; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

10.  Progesterone and estrogen receptors in conjunctival melanoma and nevi.

Authors:  Laura Bredow; Lisa Stützel; Daniel Böhringer; Enken Gundlach; Thomas Reinhard; Claudia Auw-Haedrich
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-26       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.